Allogeneic Cell Therapy Market To Reach $1.72 Billion By 2030

March 2023 | Report Format: Electronic (PDF)

Allogeneic Cell Therapy Market Growth & Trends

The global allogeneic cell therapy market size is expected to reach USD 1.72 billion by 2030, expanding at 27.40% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc.Allogeneic cell therapy involves transferring cells from healthy donors to patients to treat chronic diseases such as cancer and cardiovascular diseases. The donor cells can be directly administered to genetically similar patients or added to a cell bank.

The therapies are typically produced in large batches from different donor tissues like bone marrow, and the manufacturing process is similar to that used for protein drugs and other large-scale derived materials. Allogeneic cell therapies offer several benefits over autologous therapies, including being less expensive and their availability as a scalable off-the-shelf product. As a result, the adoption of such therapies is increasing with several biotechnology companies conducting clinical trials treatment of various diseases.

There has been a significant increase in the number of allogeneic cell-based therapy clinical trials in recent years. According to the US National Institutes of Health, the number of mesenchymal stem cell (MSC) based clinical trials using cellular therapy has doubled over the last five years, with 1014 MSC-based clinical trials registered in the government database as either completed or in the process as of July 14^th, 2021. This growth in clinical trials, combined with advancements in precision medicine and increased cell therapy production facilities is expected to drive market growth in the coming years.

The rising number of regulatory approvals for allogeneic cell-based therapies is expected to boost market growth over the forecast period. For instance, in October 2021, Enzyvant was granted FDA approval for its RETHYMIC, a single-dose regenerative tissue-based therapy for immunological reconstitution in pediatric patients with congenital athymia.

Moreover, in August 2022, Charles River Laboratories received approval from the European Medicines Agency (EMA) for its Memphis cell therapy manufacturing facility, which will enable the commercial production of allogeneic cell therapy. This approval is another significant milestone for the market, as it opens up new possibilities for treating various chronic diseases.

The COVID-19 pandemic had an unfavorable impact on the allogeneic stem cell therapy industry, causing a decline in research and development activities. This has disrupted various processes, including research, clinical trials, manufacturing, and logistics, ultimately affecting the quality of clinical evidence for cell and gene therapies. As a result, evaluating the treatment benefits and economic impacts of these therapies has become more challenging.

However, the pandemic has also raised awareness about the use of cell therapy as a potential treatment option for COVID-19. This increasing awareness is expected to have a positive impact on the market in the coming years. For instance, in May 2020, Lineage Cell Therapeutics received USD 5 million in emergency funding from the California Institute for Regenerative Medicine (CIRM) to develop a potential vaccine against SARS-CoV-2 using VAC, their allogeneic dendritic cell therapy.

The key players in the market are implementing several strategic initiatives to develop novel offerings. For instance, in February 2022, ONK Therapeutics entered into a collaboration with Intellia Therapeutics to develop five allogeneic NK cell therapies using Intellia's genome editing platform. This strategic partnership is expected to accelerate the development of novel therapies and contribute to high market growth.

key Request a free sample copy or view report summary: Allogeneic Cell Therapy Market Report

Allogeneic Cell Therapy Market Report Highlights

The stem cell therapies segment held the largest share of 77.00% in 2022. Allogeneic stem cell therapy is most frequently used to treat chronic diseases like blood cancers, leukemia, and lymphoma as well as specialized blood or autoimmune disorders
By therapeutic area, the hematological disorders segments accounted for the largest share of 58.22% in the global allogeneic cell therapy industry in 2022. Since leading market players are implementing several strategic plans into action to create cutting-edge allogeneic cell therapies for hematological disease treatment
North America held the largest market share of 80.42% in 2022. This can be attributed to the presence of the major global players in the market, and growing investments from public and private organizations for proteomic and life science research in the region

Allogeneic Cell Therapy Market Segmentation

Grand View Research has segmented the global allogeneic cell therapy market based on therapy type, therapeutic area, and region:

Allogeneic Cell Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
Non-stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others